Boehringer Ingelheim is one of the leading companies for development and manufacture of biopharmaceuticals by offering the entire production technology chain at its biopharmaceutical facilities in Biberach (Germany), in Fremont (USA) and in Vienna (Austria).
Among the world's top biopharmaceutical companies
All of the elements required for outsourcing biopharmaceutical development and manufacture, from high expression system to fill & finish, and patient convenient application systems can be found within the corporate capabilities of Boehringer Ingelheim in a so called One-Stop-Shop. At our large-scale production sites in Vienna, Austria and Biberach, Germany we have extablished a strong track record in regulatory approval since more than 25 years. So far 19 DNA-derived biopharmaceutical products have been successfully introduced to the market.
A well-filled R&D pipeline
One of our major efforts is the development of new biological entities (NBEs) for the treatment of diseases in the areas of: